Delayed use of eribulin in a heavily pretreated liposarcoma patient, previously misdiagnosed as leiomyosarcoma.
Future Oncol
; 16(1s): 9-13, 2020 Jan.
Article
em En
| MEDLINE
| ID: mdl-31916463
ABSTRACT
Due to its low incidence, liposarcoma displays a limited number of therapeutic options. However, eribulin recently received approval for the treatment of advanced liposarcoma patients, progressing to at least two chemotherapy lines. We report herein the case of a man initially diagnosed with a leyomiosarcoma, subsequently reclassified as a dedifferentiated liposarcoma, who received eribulin after he failed several therapy lines. Eribulin provided our patient an 8-month disease control and a substantial clinical benefit with no relevant adverse effects, showing a good efficacy and safety profile despite its delayed employ. Additionally, this case strengthens the pivotal importance of molecular profiling in the management of soft tissue sarcomas.
Palavras-chave
Texto completo:
1
Bases de dados:
MEDLINE
Assunto principal:
Furanos
/
Cetonas
/
Leiomiossarcoma
/
Antineoplásicos
Tipo de estudo:
Diagnostic_studies
/
Etiology_studies
Limite:
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Itália